Weikang Bio-Technology Group Co., Inc. Announces Fiscal Year 2011 Financial Results
HARBIN, China, April 2, 2012 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (WKBT.PK)("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritiona...
Weikang Bio-Technology Group Co., Inc. Is Expected to Achieve the Net Profit of at Least $26 Million
HARBIN, China, Feb. 27, 2012 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (WKBT.PK)("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutritiona...
Weikang Bio-Technology Announces Fiscal 2010 Financial Results
-- Revenue Rises 57.0% to $74.6 Million -- Adjusted Operating Income Climbs to $37.6 Million -- Adjusted* Net Income Hits $28.3 Million or $0.95 Per Share -- GAAP Net Income Up 56.5% to $24.4 Million or $0.87 Per Share HARBIN, China, March 22, 2011 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Tech...
Weikang Bio-Technology to Present at Rodman & Renshaw Annual China Investment Conference
HARBIN, China, March 4, 2011 /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nu...
Weikang Bio-Technology Announces Completion of $5.0 Million Private Placement
Over-Subscribed Offering Proceeds to Drive Media Campaign for Product Awareness HARBIN, China, Feb. 1, 2011/PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Med...
Weikang Bio-Technology Announces Inclusion of Ranitidine Hydrochloride Capsule on National Drug Reimbursement List
HARBIN, China, Jan. 27, 2011 /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nu...
Weikang Bio-Technology Announces Fourth Quarter Revenue Contribution from Newest Sales Agents
HARBIN, China, Jan. 24, 2011 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other hea...
Weikang Bio-Technology Expects to Report Fiscal 2010 Revenue of $77.8 Million and Net Income of $31.2 Million or $1.04 Earnings per Share
HARBIN, China, Jan. 18, 2011 /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals, and other health and n...
Weikang Bio-Technology Engages RedChip Companies to Lead Public and Investor Relations Efforts
HARBIN, China, Jan. 12, 2011 /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nu...
Weikang Bio-Technology Announces Update on Newest Products
HARBIN, China, Jan. 11, 2011 /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nu...
Weikang Bio-Technology Issues Fiscal 2011 Revenue Guidance of $71 - $82 Million and Net Profit of $27 - $31 million or $0.97 - $1.12 Earnings per Share
HARBIN, China, Nov. 29, 2010 /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nu...
Weikang Bio-Technology to Present at PHARMCHINA'S 64th National Drug Fair Conference
HARBIN, China, Nov. 24, 2010 /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nu...
Weikang Bio-Technology Signs Three New Agent Contracts Which are Expected to Add $15 Million in Annual Sales
HARBIN, China, Nov. 22, 2010 /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nu...
Weikang Bio-Technology Reports Record Third Quarter 2010 Financial Results; Revenue of $17 Million and Non-GAAP Net Income of $6.5 Million or $0.23 Earnings per Share
-- $30 Million in Cash and Equivalents -- Revenue of $41.9 million for the First Nine Months -- Non-GAAP Net Income of $14.8 million or $.53 EPS for the First Nine Months HARBIN, China, Nov. 15, 2010 /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang...
Weikang Bio-Technology to Announce Third Quarter Earnings on Monday, November 15
HARBIN, China, Nov. 11, 2010 /PRNewswire-Asia-FirstCall / -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other he...
Weikang Bio-Technology Reiterates Fiscal 2010 Revenue Guidance of $55 Million and Net Profit of $21 Million for $0.75 Earnings per Share
HARBIN, China, Oct. 11 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health an...
Weikang Bio-Technology Plans to Launch New Therapeutics in First Quarter 2011
HARBIN, China, Oct. 4 /PRNewswire-Asia-FirstCall / -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT( http://studio-5.financialcontent.com/prnews?Page=Quote&Ticker=WKBT )) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (...
Weikang Bio-Technology Launches New Good Health Package
HARBIN, China, Sept. 30 /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nutriti...
Weikang Bio-Technology Issues 2010 and 2011 Fiscal Year Guidance
HARBIN, China, Sept. 14 /PRNewswire-Asia/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other health and nu...
Weikang Bio-Technology to Present at Rodman and Renshaw's Annual Global Investment Conference on September 14th 2010
HARBIN, China, Sept. 7 /PRNewswire-Asia-FirstCall/ -- Weikang Bio-Technology Group Co., Inc. (OTC Bulletin Board: WKBT) ("Weikang" or the "Company"), a leading developer, manufacturer and marketer of Traditional Chinese Medicine (TCM), Western prescription and OTC pharmaceuticals and other healt...
